SPLEIßEN WEGE BIO (SWB)

SWB will use state-of-the-art technology to produce high-specialty APIs to expand the market in some catastrophic diseases, according to worldwide regulations.

Company Summary

This is a technology-driven business. SWB is intended to produce recombinant proteins for human therapy, as raw materials (APIs), for the pharma industry, by means of mammalian cells culture and SUT (Single Use Technology). We will have a very slender structure due to process automation. Our staff is highly specialized (Molecular Biology, Biochemistry, etc.). We’ll have alliances with major pharma companies and global distributors of APIs.

Team

  • Carlos Manzo

  • Arturo Manzo-Fontes
    Vicepresident and Director of Operations

    Dr. Manzo was cofounder and Director of Operations of our former company INDUSTRIA BIOTECNOLÓGICA VON MEIDING. He was appointed Director of Biotechnology Projects, Research & Development Dept. of GRUPO IFACO, from 2000 to 2006. He graduated from the UNIVERSIDAD AUTÓNOMA DE GUADALAJARA in 1982 with a bachelor’s degree in Biology; in 2000 he graduated from the UNIVERSITY OF HOUSTON with a Doctorate of Philosophy (Ph.D.), specialty in Biochemistry

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free